Navigation Links
Symposium at Angioplasty Summit TCT Asia Pacific 2008 Features OrbusNeich's Genous(TM) Bio-engineered R stent(TM)
Date:4/22/2008

HONG KONG, April 22 /PRNewswire/ -- OrbusNeich's Genous Bio-engineered R stent will be featured at a sponsored symposium during Angioplasty Summit TCT 2008 Asia Pacific.

The symposium, which will take place on April 23 at the Convention Center of Sheraton Grande Walkerhill Seoul Hotel in Seoul, Korea, includes:
-- "Opening Address" by Seung-Jung Park, the symposium's chairperson, from

12:30 p.m.-12:35 p.m.

-- "Endothelial Progenitor Cell Capture Technology and Beyond" by Michael

Kutryk from 12:35 p.m.-12:50 p.m.

-- "TRIAS HR Pilot Study Long Term Follow-up" by Robbert de Winter of the

Academic Medical Center, Amsterdam, from 12:50 p.m.-1:05 p.m.

-- "HEALING AMI" by Harry Suryapranata from 1:05 p.m.-1:20 p.m.

-- "Q&A Followed by Closing Remarks" by Seung-Jung Park from

1:20 p.m.-1:30 p.m.

"Recent data has highlighted the need for a safer alternative to drug-eluting stents," said Seung-Jung Park. "The data we have seen from both the TRIAS HR Pilot study and the registries underline Genous' superior safety profile with regards to late stage thrombosis."

Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous Bio-engineered R stent, an antibody-coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit http://www.OrbusNeich.com .


'/>"/>
SOURCE OrbusNeich
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. 5W Public Relations Presents the 2008 Body Beautiful Media Symposium Benefiting The Skin Cancer Foundation
2. Symposium to explore role nanoparticles may play in disease
3. NARSADs 5th Annual Mission Possible Symposium Offers Insight to PTSD and Other Mental Illnesses
4. Global Sound Conference Brings Worlds Top Sound Researchers, Technologists and Musicians to Los Angeles for Four Day Symposium
5. Eating Disorders Take Center Stage at iaedp(TM) 2008 Symposium in Orlando, Florida
6. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25
7. Uroplasty, Inc. Reports Presentations of Urgent(R) PC Studies at the 2008 Society of Urologic Nurses and Associates Annual Symposium
8. Seal Shield Introduces New Silver Seal Washable, Antimicrobial Mouse at HiMSS Healthcare Symposium
9. AAAS symposium to address significant effects of the male parent in reproductive success
10. Symposium on drug-resistant diseases set for annual AAAS conference
11. Studies on Urgent(R) PC to be Presented at the 2008 Society of Urologic Nurses and Associates Annual Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... its affiliation with Tennessee Counseling Association. This new relationship allows TherapySites ... Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely ...
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... ... ... a legally blind and certified personal trainer is helping to develop a weight loss fitness ... to fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... CHAPEL HILL, N.C. , June 24, 2016 ... in healthcare decisions and regulators/payers have placed more ... this new environment, patient support programs in the ... support for patients, medications. Consequently, pharmaceutical companies are ... to ensure they are providing products and services ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
Breaking Medicine Technology: